Eli Lilly Piles Up Milestones Across Oncology and Metabolism as M&A Tops $25 Billion
11.06.2026 - 06:05:10 | boerse-global.de
Eli Lilly is proving that its ambitions stretch far beyond the blockbuster weight-loss portfolio. In a span of days, the drugmaker will present pivotal cancer data in Stockholm, boast a fresh Alzheimer’s licensing deal, and celebrate a clinical win for its next-generation oral GLP-1 candidate — all while cementing its status as the industry’s most aggressive acquirer. Ten transactions have already crossed the finish line this year, collectively worth more than $25 billion and accounting for roughly half of the sector’s total M&A capacity over the period.
Analysts are taking notice. Jefferies recently raised its price target on the stock to $1,350 from $1,330, citing the breadth of the pipeline. The bank’s enthusiasm is particularly tied to orforglipn (Foundayo), which it believes could generate peak sales of up to $14 billion. The first-quarter results underpin that confidence: revenue hit $17.6 billion, handily beating the consensus estimate of $16.1 billion.
Oncology Takes the Spotlight in Stockholm
The European Hematology Association (EHA) meeting opening on June 14 marks a critical moment for Lilly’s oncology push. The company will unveil detailed phase?3 data from the BRUIN study of Jaypirca in chronic lymphocytic leukemia. The drug has already met its primary endpoint, significantly extending progression?free survival against the control arm — a first in that treatment setting. Investors are waiting for the exact numbers.
Two recently announced acquisitions will also be in the research spotlight. Kelonia Therapeutics presents a novel CAR?T therapy for multiple myeloma on the first day, while Ajax Therapeutics follows on Saturday with clinical data for a JAK2 inhibitor. Lilly expects both takeovers to close in the second half of the year.
Should investors sell immediately? Or is it worth buying Eli Lilly?
Jaypirca’s commercial traction is already building. First?quarter sales jumped 79% year?on?year to $165 million, albeit from a small base. The oncology franchise remains a minor contributor next to the metabolic juggernaut, but the trajectory is encouraging.
An Oral Alzheimer Candidate Joins the Pipeline
On the M&A front, June brought a licensing agreement with AlzeCure for the oral gamma?secretase modulator ACD680. The deal is worth up to $1 billion, with a $10 million upfront payment and the remainder tied to milestones. The candidate reduces production of A?42 and could offer an oral alternative to injectable antibody therapies such as Kisunla. Alzheimer’s is one of several areas where Lilly is layering early?stage bets onto a mature late?stage portfolio.
GLP?1 Data Reinforce a Dominant Hand
At the American Diabetes Association meeting, Lilly presented strong results for two key metabolic assets. In the Triumph?1 phase?3 study, Retatrutide produced up to 28.3% weight loss after 80 weeks, along with measurable improvements in sleep apnea and chronic pain. The oral GLP?1 drug Foundayo (orforglipron) outperformed oral semaglutide in the Achieve?3 trial, lowering HbA1c by 2.2 percentage points versus 1.4 points over 52 weeks.
TD Cowen subsequently raised its global GLP?1 market forecast for 2030 to $150 billion, with Lilly expected to capture around 62% of that pie. The competitive moat is widening.
Eli Lilly at a turning point? This analysis reveals what investors need to know now.
Regulatory Wins and Geographic Expansion
Lilly is also chalking up regulatory victories outside the core metabolic and oncology fields. The FDA expanded the label for Ebglyss, the eczema treatment, so patients now need only six injections per year — a clear convenience advantage over more frequent alternatives. In Canada, Quebec’s public drug plan began covering Verzenio for breast cancer at the end of May 2026, opening a new reimbursement channel.
Stock Momentum Remains Intact
The shares are trading around €990, roughly 5% below the 52?week high of €1,044 and about 16% above the 50?day moving average. The relative?strength index stands at 68.8, just shy of the 70 threshold that often signals overbought conditions. After a 40% gain over the past 12 months — and a 20% run in the last 30 days alone — a consolidation phase is technically plausible. But with a pipeline that keeps delivering across multiple therapeutic fronts, the fundamental story shows no signs of slowing.
Ad
Eli Lilly Stock: New Analysis - 11 June
Fresh Eli Lilly information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
